XML 457 R130.htm IDEA: XBRL DOCUMENT
v3.26.1

Other disclosures - Subsidiaries and other investments (Details) | Dec. 31, 2025 | Dec. 30, 2025 | Oct. 31, 2025 | Jun. 30, 2025
--- | --- | --- | --- | ---
Aeovian Pharmaceuticals Inc., San Francisco, United States |  |  |  |
Interests in other entities |  |  |  |
Voting rights % held in other investments | 2.32% |  |  |
Voting rights % in investments held for sale | 2.32% |  |  |
ArgoBio SAS, Paris, France |  |  |  |
Interests in other entities |  |  |  |
Voting rights % held in other investments | 8.17% |  |  |
Aurobac Therapeutics SAS, Lyon, France |  |  |  |
Interests in other entities |  |  |  |
Voting rights % held in other investments | 12.50% |  |  |
Autobahn Labs, LLC, Palo Alto, CA USA |  |  |  |
Interests in other entities |  |  |  |
Voting rights % held in other investments | 10.53% |  |  |
Blacksmith Medicines Inc., San Diego, CA USA |  |  |  |
Interests in other entities |  |  |  |
Voting rights % held in other investments | 17.97% |  |  |
Cajal Neuroscience Inc., Seattle, USA |  |  |  |
Interests in other entities |  |  |  |
Voting rights % held in other investments | 1.18% |  |  |
Carma Fund I, Munich, Germany |  |  |  |
Interests in other entities |  |  |  |
Voting rights % held in other investments | 10.00% |  |  |
Celmatix Inc., New York, USA |  |  |  |
Interests in other entities |  |  |  |
Voting rights % held in other investments | 7.47% |  |  |
Curie Bio LLC, Boston, United States |  |  |  |
Interests in other entities |  |  |  |
Voting rights % held in other investments | 0.10% |  |  |
Curie Bio Seed Fund I LP, Boston, USA |  |  |  |
Interests in other entities |  |  |  |
Voting rights % held in other investments | 2.83% |  |  |
Extend S.r.l., Rome, Italy |  |  |  |
Interests in other entities |  |  |  |
Voting rights % held in other investments | 9.10% |  |  |
Fibrocor LLP, Toronto, Canada |  |  |  |
Interests in other entities |  |  |  |
Voting rights % held in other investments | 16.26% |  |  |
Fibrocor Therapeutics, Inc., Toronto, Canada |  |  |  |
Interests in other entities |  |  |  |
Voting rights % held in other investments | 7.65% |  |  |
IMIDomics Inc., San Rafael, CA, USA |  |  |  |
Interests in other entities |  |  |  |
Voting rights % held in other investments | 6.64% |  |  |
Immunitas Therapeutics Inc., Waltham, USA |  |  |  |
Interests in other entities |  |  |  |
Voting rights % held in other investments | 5.54% |  |  |
Leon Nanodrugs GmbH, Munich, Germany |  |  |  |
Interests in other entities |  |  |  |
Voting rights % held in other investments | 3.99% |  |  |
Mission BioCapital V LP, Cambridge, United States |  |  |  |
Interests in other entities |  |  |  |
Voting rights % held in other investments | 3.64% |  |  |
Pluristyx Inc., Seattle, USA |  |  |  |
Interests in other entities |  |  |  |
Voting rights % held in other investments | 3.79% |  |  |
Sernova Corp., Ontario, Canada |  |  |  |
Interests in other entities |  |  |  |
Voting rights % held in other investments | 4.73% |  |  |
Thelior Bio, Oxford, UK |  |  |  |
Interests in other entities |  |  |  |
Voting rights % held in other investments | 1.18% |  |  |
Tubulis GmbH, Munich, Germany |  |  |  |
Interests in other entities |  |  |  |
Voting rights % held in other investments | 3.33% |  |  |
Verto Therapeutics Inc., Boston, USA |  |  |  |
Interests in other entities |  |  |  |
Voting rights % held in other investments | 4.16% |  |  |
OxVax Ltd., Oxford, UK |  |  |  |
Interests in other entities |  |  |  |
Voting rights % disposed of |  |  |  | 15.33%
Carrick Therapeutics Inc., Boston, USA |  |  |  |
Interests in other entities |  |  |  |
Voting rights % disposed of |  |  | 2.86% |
Breakpoint Therapeutics GmbH, Hamburg, Germany |  |  |  |
Interests in other entities |  |  |  |
Voting rights % held in associates | 34.03% |  |  |
Centauri Therapeutics Ltd., Cheshire, UK |  |  |  |
Interests in other entities |  |  |  |
Voting rights % held in associates | 22.18% |  |  |
EIR Biotherapies S.r.l., Mirandola (MO), Italy |  |  |  |
Interests in other entities |  |  |  |
Voting rights % held in associates | 24.66% |  |  |
Eternygen GmbH, Berlin, Germany |  |  |  |
Interests in other entities |  |  |  |
Voting rights % held in associates | 24.97% |  |  |
Quantro Therapeutics GmbH, Wien, Austria |  |  |  |
Interests in other entities |  |  |  |
Voting rights % held in associates | 38.79% |  |  |
TAG Therapeutics GmbH, Vienna, Austria |  |  |  |
Interests in other entities |  |  |  |
Voting rights % held in associates | 20.16% |  |  |
Topas Therapeutics GmbH, Hamburg, Germany |  |  |  |
Interests in other entities |  |  |  |
Voting rights % held in associates | 23.86% |  |  |
Dark Blue Therapeutics LTD, Oxford, United Kingdom |  |  |  |
Interests in other entities |  |  |  |
Voting rights % disposed of |  | 21.67% |  |
Aptuit Global LLC, Princeton, United States |  |  |  |
Interests in other entities |  |  |  |
Voting rights % held in subsidiary | 100.00% |  |  |
Aptuit (Verona) SRL, Verona, Italy |  |  |  |
Interests in other entities |  |  |  |
Voting rights % held in subsidiary | 100.00% |  |  |
Aptuit (Oxford) Ltd., Abingdon, United Kingdom |  |  |  |
Interests in other entities |  |  |  |
Voting rights % held in subsidiary | 100.00% |  |  |
Cyprotex Discovery Ltd., Manchester, United Kingdom |  |  |  |
Interests in other entities |  |  |  |
Voting rights % held in subsidiary | 100.00% |  |  |
Cyprotex Ltd., Manchester, United Kingdom |  |  |  |
Interests in other entities |  |  |  |
Voting rights % held in subsidiary | 100.00% |  |  |
Cyprotex US, LLC., Framingham, United States |  |  |  |
Interests in other entities |  |  |  |
Voting rights % held in subsidiary | 100.00% |  |  |
Evotec (France) SAS, Toulouse, France |  |  |  |
Interests in other entities |  |  |  |
Voting rights % held in subsidiary | 100.00% |  |  |
Evotec ID (Lyon) SAS, Marcy l'Etoile, France |  |  |  |
Interests in other entities |  |  |  |
Voting rights % held in subsidiary | 100.00% |  |  |
Evotec (Hamburg) GmbH, Hamburg, Germany |  |  |  |
Interests in other entities |  |  |  |
Voting rights % held in subsidiary | 100.00% |  |  |
Evotec GT GmbH, Orth an der Donau, Austria |  |  |  |
Interests in other entities |  |  |  |
Voting rights % held in subsidiary | 100.00% |  |  |
Evotec (India) Private Limited, Thane, India* |  |  |  |
Interests in other entities |  |  |  |
Voting rights % held in subsidiary | 100.00% |  |  |
Evotec International GmbH, Hamburg, Germany |  |  |  |
Interests in other entities |  |  |  |
Voting rights % held in subsidiary | 100.00% |  |  |
Evotec (UK) Ltd., Abingdon, United Kingdom |  |  |  |
Interests in other entities |  |  |  |
Voting rights % held in subsidiary | 100.00% |  |  |
Evotec (US), Inc., Princeton, United States |  |  |  |
Interests in other entities |  |  |  |
Voting rights % held in subsidiary | 100.00% |  |  |
Just-Evotec Biologics, Inc, Seattle, United States |  |  |  |
Interests in other entities |  |  |  |
Voting rights % held in subsidiary | 100.00% |  |  |
Evotec (Modena) Srl., Medolla, Italy |  |  |  |
Interests in other entities |  |  |  |
Voting rights % held in subsidiary | 100.00% |  |  |
NephThera GmbH, Hamburg, Germany |  |  |  |
Interests in other entities |  |  |  |
Voting rights % held in subsidiary | 100.00% |  |  |
Evotec Asia Pte. Ltd., Shenton, Singapore |  |  |  |
Interests in other entities |  |  |  |
Voting rights % held in subsidiary | 100.00% |  |  |

X
- Definition Interests in other entities + References No definition available. + Details
Name: | evo_InterestsInOtherEntitiesLineItems
Namespace Prefix: | evo_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The proportion of the voting rights in other investments held by the entity. + References No definition available. + Details
Name: | evo_ProportionOfVotingPowerHeldInOtherInvestments
Namespace Prefix: | evo_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Proportion of voting rights disposed of + References No definition available. + Details
Name: | evo_ProportionOfVotingRightsDisposedOf
Namespace Prefix: | evo_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Proportion of voting rights in investments held for sale + References No definition available. + Details
Name: | evo_ProportionOfVotingRightsInInvestmentsHeldForSale
Namespace Prefix: | evo_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | instant

X
- Definition The proportion of the voting rights in an associate held by the entity. [Refer: Total for all associates [member]] + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Name IAS -Number 27 -IssueDate 2025-01-01 -Paragraph 17 -Subparagraph b -Clause iii -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=27&code=ifrs-tx-2025-en-r&anchor=para_17_b_iii&doctype=Standard -URIDate 2025-03-27 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Name IAS -Number 27 -IssueDate 2025-01-01 -Paragraph 16 -Subparagraph b -Clause iii -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=27&code=ifrs-tx-2025-en-r&anchor=para_16_b_iii&doctype=Standard -URIDate 2025-03-27 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Name IFRS -Number 12 -IssueDate 2025-01-01 -Paragraph 21 -Subparagraph a -Clause iv -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2025-en-r&anchor=para_21_a_iv&doctype=Standard -URIDate 2025-03-27 + Details
Name: | ifrs-full_ProportionOfVotingPowerHeldInAssociate
Namespace Prefix: | ifrs-full_
Data Type: | dtr-2022:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition The proportion of the voting rights in a subsidiary held by the entity. [Refer: Total for all subsidiaries [member]] + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Name IAS -Number 27 -IssueDate 2025-01-01 -Paragraph 17 -Subparagraph b -Clause iii -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=27&code=ifrs-tx-2025-en-r&anchor=para_17_b_iii&doctype=Standard -URIDate 2025-03-27 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Name IAS -Number 27 -IssueDate 2025-01-01 -Paragraph 16 -Subparagraph b -Clause iii -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=27&code=ifrs-tx-2025-en-r&anchor=para_16_b_iii&doctype=Standard -URIDate 2025-03-27 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Name IFRS -Number 12 -IssueDate 2025-01-01 -Paragraph 19B -Subparagraph c -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2025-en-r&anchor=para_19B_c&doctype=Standard -URIDate 2025-03-27 + Details
Name: | ifrs-full_ProportionOfVotingPowerHeldInSubsidiary
Namespace Prefix: | ifrs-full_
Data Type: | dtr-2022:percentItemType
Balance Type: | na
Period Type: | duration

X
- Details
Name: | evo_OtherInvestmentAxis=evo_AeovianPharmaceuticalsInc.SanFranciscoUsaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | evo_OtherInvestmentAxis=evo_AgrobioSasParisFranceMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | evo_OtherInvestmentAxis=evo_AurobacTherapeuticsSasLyonFranceMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | evo_OtherInvestmentAxis=evo_AutobahnLabsPaloAltoUsaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | evo_OtherInvestmentAxis=evo_BlacksmithMedicinesInc.SanDiegoUsaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | evo_OtherInvestmentAxis=evo_CajalNeuroscienceInc.SeattleUsaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | evo_OtherInvestmentAxis=evo_CarmaFundIMunichGermanyMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | evo_OtherInvestmentAxis=evo_CelmatixInc.NewYorkUsaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | evo_OtherInvestmentAxis=evo_CurieBioLlcBostonUsaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | evo_OtherInvestmentAxis=evo_CurieBioSeedFundIL.p.BostonUsaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | evo_OtherInvestmentAxis=evo_ExtendSrlRomeItalyMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | evo_OtherInvestmentAxis=evo_FibrocorLlpTorontoCanadaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | evo_OtherInvestmentAxis=evo_FibrocorTherapeuticsInc.TorontoCanadaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | evo_OtherInvestmentAxis=evo_ImidomicsInc.SanFranciscoUsaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | evo_OtherInvestmentAxis=evo_ImmunitasTherapeuticsInc.WalthamUsaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | evo_OtherInvestmentAxis=evo_LeonNanodrugsGmbhMnchenGermanyMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | evo_OtherInvestmentAxis=evo_MissionBiocapitalVLpCambridgeUsaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | evo_OtherInvestmentAxis=evo_PluristyxInc.SeattleUsaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | evo_OtherInvestmentAxis=evo_SernovaCorp.OntarioCanadaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | evo_OtherInvestmentAxis=evo_TheliorBioOxfordUkMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | evo_OtherInvestmentAxis=evo_TubulisGmbhMunichGermanyMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | evo_OtherInvestmentAxis=evo_VertoTherapeuticsInc.BostonUsaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | evo_OtherInvestmentAxis=evo_OxvaxLimitedOxfordUkMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | evo_OtherInvestmentAxis=evo_CarrickTherapeuticsLtd.DublinIrelandMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_SignificantInvestmentsInAssociatesAxis=evo_BreakpointTherapeuticsGmbhHamburgGermanyMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_SignificantInvestmentsInAssociatesAxis=evo_CentauriTherapeuticsLtd.CheshireUkMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_SignificantInvestmentsInAssociatesAxis=evo_EirBiotherapiesS.r.l.MirandolaMoItalyMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_SignificantInvestmentsInAssociatesAxis=evo_EternygenGmbhBerlinGermanyMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_SignificantInvestmentsInAssociatesAxis=evo_QuantroTherapeuticsGmbhWienAustriaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_SignificantInvestmentsInAssociatesAxis=evo_TagTherapeuticsGmbhViennaAustriaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_SignificantInvestmentsInAssociatesAxis=evo_TopasTherapeuticsGmbhHamburgGermanyMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_SignificantInvestmentsInAssociatesAxis=evo_DarkBlueTherapeuticsLtdOxfordUkMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_SignificantInvestmentsInSubsidiariesAxis=evo_AptuitGlobalLlcPrincetonUsaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_SignificantInvestmentsInSubsidiariesAxis=evo_AptuitVeronaSrlVeronaItalyMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_SignificantInvestmentsInSubsidiariesAxis=evo_AptuitOxfordLtd.AbingdonUkMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_SignificantInvestmentsInSubsidiariesAxis=evo_CyprotexDiscoveryLtd.ManchesterUkMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_SignificantInvestmentsInSubsidiariesAxis=evo_CyprotexLtdManchesterUkMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_SignificantInvestmentsInSubsidiariesAxis=evo_CyprotexUsLlc.FraminghamUsaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_SignificantInvestmentsInSubsidiariesAxis=evo_EvotecFranceSasToulouseFranceMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_SignificantInvestmentsInSubsidiariesAxis=evo_EvotecIdLyonSasMarcyLetoileFranceMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_SignificantInvestmentsInSubsidiariesAxis=evo_EvotecHamburgGmbhHamburgGermanyMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_SignificantInvestmentsInSubsidiariesAxis=evo_EvotecGtGmbhOrthDerDonauAustriaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_SignificantInvestmentsInSubsidiariesAxis=evo_EvotecIndiaPrivateLimitedThaneIndiaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_SignificantInvestmentsInSubsidiariesAxis=evo_EvotecInternationalGmbhHamburgGermanyMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_SignificantInvestmentsInSubsidiariesAxis=evo_EvotecUkLtd.AbingdonUkMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_SignificantInvestmentsInSubsidiariesAxis=evo_EvotecUsInc.PrincetonUsaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_SignificantInvestmentsInSubsidiariesAxis=evo_JustevotecBiologicsIncSeattleUsaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_SignificantInvestmentsInSubsidiariesAxis=evo_EvotecModenaSrl.MedollaItalyMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_SignificantInvestmentsInSubsidiariesAxis=evo_NephtheraGmbhHamburgGermanyMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_SignificantInvestmentsInSubsidiariesAxis=evo_EvotecAsiaPte.Ltd.ShentonSingaporeMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |